Top

15-12-2016 | Rheumatoid arthritis | Review | Article

Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis

Journal: Nature Reviews Rheumatology

Authors: Anca I. Catrina, Camilla I. Svensson, Vivianne Malmström, Georg Schett, Lars Klareskog

Publisher: Nature Publishing Group UK

Abstract

autoimmunity progresses to joint-specific inflammation. In patients with seropositive RA (that is, characterized by the presence of autoantibodies) evidence is accumulating that immunity against post-translationally modified (such as citrullinated) autoantigens might be triggered in mucosal organs, such as the lung, long before the first signs of inflammation are seen in the joints. However, the mechanism by which systemic autoimmunity specifically homes to the joint and bone compartment, thereby triggering inflammation, remains elusive. This Review summarizes potential pathways involved in this joint-homing mechanism, focusing particularly on osteoclasts as the primary targets of anti-citrullinated protein antibodies (ACPAs) in the bone and joint compartment. Osteoclasts are dependent on citrullinating enzymes for their normal differentiation and are unique in displaying citrullinated antigens on their cell surface in a non-inflamed state. The binding of ACPAs to osteoclasts releases the chemokine IL-8, leading to bone erosion and pain. This process initiates a chain of events that could lead to attraction and activation of neutrophils, resulting in a complex series of proinflammatory processes in the synovium, eventually leading to RA.

Nat Rev Rheumatol 2017;13:79–86. doi:10.1038/nrrheum.2016.200

Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659–672 (2009).PubMedCrossRef

Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).CrossRefPubMed

Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741–2749 (2003).CrossRefPubMed

Brink, M. et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 65, 899–910 (2013).CrossRefPubMed

Chibnik, L. B., Mandl, L. A., Costenbader, K. H., Schur, P. H. & Karlson, E. W. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J. Rheumatol. 36, 706–711 (2009).PubMedPubMedCentralCrossRef

Koppejan, H. et al. Anti-carbamylated protein antibodies in rheumatoid arthritis, first-degree relatives and controls: comparison to anti-citrullinated protein antibodies. Arthritis Rheumatol. 68, 2090–2098 (2016).PubMedPubMedCentralCrossRef

Brink, M. et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res. Ther. 17, 25 (2015).PubMedPubMedCentralCrossRef

Shi, J. et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 73, 780–783 (2014).CrossRefPubMed

Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).PubMedPubMedCentralCrossRef

10.

Catrina, A. I., Ytterberg, A. J., Reynisdottir, G., Malmstrom, V. & Klareskog, L. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat. Rev. Rheumatol. 10, 645–653 (2014).PubMedCrossRef

11.

Chatzidionisyou, A. & Catrina, A. I. The lung in rheumatoid arthritis, cause or consequence? Curr. Opin. Rheumatol. 28, 76–82 (2016).PubMedCrossRef

12.

Catrina, A. I., Deane, K. D. & Scher, J. U. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology (Oxford) 55, 391–402 (2016).

13.

Leech, M. T. & Bartold, P. M. The association between rheumatoid arthritis and periodontitis. Best Pract. Res. Clin. Rheumatol. 29, 189–201 (2015).PubMedCrossRef

14.

Koziel, J., Mydel, P. & Potempa, J. The link between periodontal disease and rheumatoid arthritis: an updated review. Curr. Rheumatol. Rep. 16, 408 (2014).PubMedPubMedCentralCrossRef

15.

Payne, J. B., Golub, L. M., Thiele, G. M. & Mikuls, T. R. The Link Between Periodontitis and Rheumatoid Arthritis: A Periodontist's Perspective. Curr. Oral Health Rep. 2, 20–29 (2015).PubMedCrossRef

16.

Aho, K., Heliovaara, M., Maatela, J., Tuomi, T. & Palosuo, T. Rheumatoid factors antedating clinical rheumatoid arthritis. J. Rheumatol. 18, 1282–1284 (1991).PubMed

17.

Kurki, P., Aho, K., Palosuo, T. & Heliovaara, M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum. 35, 914–917 (1992).CrossRefPubMed

18.

Haj Hensvold, A. et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann. Rheum. Dis. 74, 375–380 (2013).CrossRef

19.

van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 69, 1554–1561 (2010).PubMedCrossRef

20.

van de Stadt, L. A. et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum. 63, 3226–3233 (2011).CrossRefPubMed

21.

Juarez, M. et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75, 1099–1107 (2016).CrossRefPubMed

22.

Mathsson, L. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 58, 36–45 (2008).PubMedCrossRef

23.

Kastbom, A. et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann. Rheum. Dis. 75, 356–361 (2016).PubMedCrossRef

24.

Hensvold, A. H. et al. Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res. Ther. 17, 239 (2015).PubMedPubMedCentralCrossRef

25.

Bos, W. H. et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann. Rheum. Dis. 69, 490–494 (2010).PubMedCrossRef

26.

Stack, R. J. et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford) 53, 1646–1653 (2014).CrossRef

27.

Neovius, M., Simard, J. F., Askling, J. & Group, A. S. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann. Rheum. Dis. 70, 1010–1015 (2011).PubMedCrossRef

28.

Innala, L. et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J. Rheumatol. 35, 1002–1008 (2008).PubMed

29.

Mustila, A. et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin. Exp. Rheumatol. 29, 500–505 (2011).PubMed

30.

Syversen, S. W. et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann. Rheum. Dis. 69, 345–351 (2010).PubMedCrossRef

31.

van Steenbergen, H. W., Ajeganova, S., Forslind, K., Svensson, B. & van der Helm-van Mil, A. H. The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis. Ann. Rheum. Dis. 74, e3 (2015).PubMedCrossRef

32.

Hecht, C. et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann. Rheum. Dis. 74, 2151–2156 (2015).PubMedCrossRef

33.

Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372–17377 (2011).CrossRefPubMedPubMedCentral

34.

Kleyer, A. et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann. Rheum. Dis. 75, 854–860 (2013).

35.

van Schaardenburg, D. et al. Bone metabolism is altered in preclinical rheumatoid arthritis. Ann. Rheum. Dis. 70, 1173–1174 (2011).PubMedCrossRef

36.

Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802 (2012).PubMedPubMedCentralCrossRef

37.

Ossipova, E. et al. Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Res. Ther. 16, R167 (2014).PubMedPubMedCentralCrossRef

38.

Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721–729 (2016).PubMedCrossRef

39.

Du, N. et al. Cell surface vimentin is an attachment receptor for enterovirus 71. J. Virol. 88, 5816–5833 (2014).PubMedPubMedCentralCrossRef

40.

Amara, K. et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J. Exp. Med. 210, 445–455 (2013).PubMedPubMedCentralCrossRef

41.

Negishi-Koga, T. et al. Immune complexes regulate bone metabolism through FcRgamma signalling. Nat. Commun. 6, 6637 (2015).PubMedCrossRef

42.

Harre, U. et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat. Commun. 6, 6651 (2015).PubMedCrossRef

43.

Rombouts, Y. et al. Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann. Rheum. Dis. 75, 578–585 (2016).CrossRefPubMed

44.

Wigerblad, G. et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann. Rheum. Dis. 75, 730–738 (2016).PubMedCrossRef

45.

Moscarello, M. A., Wood, D. D., Ackerley, C. & Boulias, C. Myelin in multiple sclerosis is developmentally immature. J. Clin. Invest. 94, 146–154 (1994).PubMedPubMedCentralCrossRef

46.

Beniac, D. R. et al. Cryoelectron microscopy of protein-lipid complexes of human myelin basic protein charge isomers differing in degree of citrullination. J. Struct. Biol. 129, 80–95 (2000).PubMedCrossRef

47.

Senshu, T., Kan, S., Ogawa, H., Manabe, M. & Asaga, H. Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochem. Biophys. Res. Commun. 225, 712–719 (1996).PubMedCrossRef

48.

Senshu, T., Akiyama, K. & Nomura, K. Identification of citrulline residues in the V subdomains of keratin K1 derived from the cornified layer of newborn mouse epidermis. Exp. Dermatol. 8, 392–401 (1999).PubMedCrossRef

49.

Harding, C. R. & Scott, I. R. Histidine-rich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation. J. Mol. Biol. 170, 651–673 (1983).PubMedCrossRef

50.

Pearton, D. J., Dale, B. A. & Presland, R. B. Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. J. Invest. Dermatol. 119, 661–669 (2002).PubMedCrossRef

51.

Scott, I. R., Harding, C. R. & Barrett, J. G. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim. Biophys. Acta 719, 110–117 (1982).PubMedCrossRef

52.

Makrygiannakis, D. et al. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 65, 1219–1222 (2006).PubMedPubMedCentralCrossRef

53.

Rothe, L. et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 139, 4353–4363 (1998).PubMedCrossRef

54.

Kopesky, P. et al. Autocrine signaling is a key regulatory element during osteoclastogenesis. Biol. Open 3, 767–776 (2014).PubMedPubMedCentralCrossRef

55.

van Steenbergen, H. W., Mangnus, L., Reijnierse, M., Huizinga, T. W. & van der Helm-van Mil, A. H. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann. Rheum. Dis. 75, 1824–1830 (2016).CrossRefPubMed

56.

van de Stadt, L. A. et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann. Rheum. Dis. 70, 128–133 (2011).PubMedCrossRef

57.

Nam, J. L., Hunt, L., Hensor, E. M. & Emery, P. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. Ann. Rheum. Dis. 75, 1452–1456 (2016).PubMedCrossRef

58.

Rakieh, C. et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann. Rheum. Dis. 74, 1659–1666 (2015).CrossRefPubMed

59.

Andoh, T. & Kuraishi, Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. FASEB J. 18, 182–184 (2004).PubMedCrossRef

60.

Qu, L., Zhang, P., LaMotte, R. H. & Ma, C. Neuronal Fc-gamma receptor I mediated excitatory effects of IgG immune complex on rat dorsal root ganglion neurons. Brain Behav. Immun. 25, 1399–1407 (2011).PubMedPubMedCentralCrossRef

61.

Cunha, T. M. et al. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc. Natl Acad. Sci. USA 102, 1755–1760 (2005).PubMedCrossRefPubMedCentral

62.

Guerrero, A. T. et al. Toll-like receptor 2/MyD88 signaling mediates zymosan-induced joint hypernociception in mice: participation of TNF-alpha, IL-1beta and CXCL1/KC. Eur. J. Pharmacol. 674, 51–57 (2012).PubMedCrossRef

63.

Qin, X., Wan, Y. & Wang, X. CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons. J. Neurosci. Res. 82, 51–62 (2005).PubMedCrossRef

64.

Zhang, Z. J., Cao, D. L., Zhang, X., Ji, R. R. & Gao, Y. J. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain 154, 2185–2197 (2013).PubMedPubMedCentralCrossRef

65.

Wang, J. G. et al. The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons. Mol. Pain 4, 38 (2008).PubMedPubMedCentral

66.

Kuhn, K. A. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin. Invest. 116, 961–973 (2006).PubMedPubMedCentralCrossRef

67.

Sohn, D. H. et al. Local Joint inflammation and histone citrullination in a murine model of the transition from preclinical autoimmunity to inflammatory arthritis. Arthritis Rheumatol. 67, 2877–2887 (2015).PubMedPubMedCentralCrossRef

68.

Marinova-Mutafchieva, L., Williams, R. O., Funa, K., Maini, R. N. & Zvaifler, N. J. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 46, 507–513 (2002).PubMedCrossRef

69.

Hetland, M. L. et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann. Rheum. Dis. 68, 384–390 (2009).PubMedCrossRef

70.

Haavardsholm, E. A., Boyesen, P., Ostergaard, M., Schildvold, A. & Kvien, T. K. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann. Rheum. Dis. 67, 794–800 (2008).PubMedCrossRef

71.

Boyesen, P. et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann. Rheum. Dis. 70, 176–179 (2011).PubMedCrossRef

72.

McQueen, F. M. et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum. 48, 1814–1827 (2003).CrossRefPubMed

73.

Sokolove, J., Zhao, X., Chandra, P. E. & Robinson, W. H. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum. 63, 53–62 (2011).PubMedPubMedCentralCrossRef

74.

Trouw, L. A. et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 60, 1923–1931 (2009).CrossRefPubMed

75.

Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra40 (2013).PubMedPubMedCentralCrossRef

76.

Suurmond, J. et al. Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann. Rheum. Dis. 74, 1915–1923 (2015).PubMedCrossRef

77.

Habets, K. L. et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res. Ther. 17, 209 (2015).PubMedPubMedCentralCrossRef

78.

Lu, M. C. et al. Anti-citrullinated protein antibodies promote apoptosis of mature human Saos-2 osteoblasts via cell-surface binding to citrullinated heat shock protein 60. Immunobiology 221, 76–83 (2016).PubMedCrossRef

79.

Barbarroja, N. et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler, Thromb. Vasc. Biol. 34, 2706–2716 (2014).CrossRef

80.

Makrygiannakis, D. et al. Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis. Arthritis Res. Ther. 14, R20 (2012).PubMedPubMedCentralCrossRef

81.

Makrygiannakis, D. et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 67, 1488–1492 (2008).CrossRefPubMed

82.

Lugli, E. B. et al. Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Res. Ther. 17, 9 (2015).PubMedPubMedCentralCrossRef

83.

Nesse, W. et al. The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation. J. Clin. Periodontol 39, 599–607 (2012).PubMedCrossRef

84.

Bongartz, T. et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 46, 70–75 (2007).CrossRef

85.

McInnes, I. B., Buckley, C. D. & Isaacs, J. D. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat. Rev. Rheumatol. 12, 63–68 (2016).CrossRefPubMed

86.

Feldmann, M. & Maini, S. R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 223, 7–19 (2008).PubMedCrossRef

87.

Patel, R., Filer, A., Barone, F. & Buckley, C. D. Stroma: fertile soil for inflammation. Best Pract. Res. Clin. Rheumatol. 28, 565–576 (2014).PubMedCrossRef

88.

Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233–255 (2010).PubMedPubMedCentralCrossRef

89.

Chemin, K., Klareskog, L. & Malmstrom, V. Is rheumatoid arthritis an autoimmune disease? Curr. Opin. Rheumatol. 28, 181–188 (2016).PubMedCrossRef

90.

James, E. A. et al. Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol. 66, 1712–1722 (2014).PubMedPubMedCentralCrossRef

91.

Reparon-Schuijt, C. C. et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 44, 41–47 (2001).PubMedCrossRef

92.

Nandakumar, K. S. Pathogenic antibody recognition of cartilage. Cell Tissue Res. 339, 213–220 (2010).PubMedCrossRef

93.

Cook, A. D., Rowley, M. J., Mackay, I. R., Gough, A. & Emery, P. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum. 39, 1720–1727 (1996).PubMedCrossRef

94.

Lindh, I. et al. Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice. Arthritis Res. Ther. 16, R143 (2014).PubMedPubMedCentralCrossRef

95.

Ronnelid, J., Lysholm, J., Engstrom-Laurent, A., Klareskog, L. & Heyman, B. Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum. 37, 1023–1029 (1994).PubMedCrossRef

96.

Haag, S. et al. Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. Arthritis Rheumatol. 66, 1440–1449 (2014).PubMedCrossRef

97.

Turunen, S., Hannonen, P., Koivula, M. K., Risteli, L. & Risteli, J. Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides. Arthritis Res. Ther. 17, 2 (2015).PubMedPubMedCentralCrossRef

98.

Lundberg, K. et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann. Rheum. Dis. 72, 652–658 (2013).CrossRefPubMed

99.

Ditzel, H. J. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol. Med. 10, 40–45 (2004).PubMedCrossRef

100.

Reynisdottir, G. et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann. Rheum. Dis. 75, 1722–1727 (2016).PubMedCrossRef

101.

Medicine Matters Rheumatology

Abstract